Pre-Lunch Industry Symposium :
Clinical utility of the 7-gene predictive DCIS test to accurately stratify risk and predict radiation benefit vs. clinicopathologic tools alone
Supported by PreludeDx
Thursday, September 12, 2024
12:30-13:30
HALL B
| 12:30-12:45 | The development of DCISionRT for recurrence risk and prediction of RT benefit in DCIS patients, and discussion of other DCIS assays and ClinPath nomograms Pat Whitworth, Nashville, TN, USA |
| 12:45-13:00 | Avoiding under- and over-treatment in DCIS. Clinical data and clinical utility Frank A. Vicini, Farmington Hills, MI, USA |
| 13:00-13:15 | Utilization of DCISionRT and management of patients in Australia, and future opportunities and developments Bruce Mann, Melbourne, Australia |
| 13:15-13:30 | Panel Discussion Q&A Anita Skandarajah, Melbourne, Australia Pat Whitworth, Nashville, TN, USA Frank A. Vicini, Farmington Hills, MI, USA Bruce Mann, Melbourne, Australia |